B.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research ...
Zacks Small Cap Issues Negative Outlook for ARWR Earnings
Equities researchers at Zacks Small Cap lowered their Q2 2025 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a report issued on Wednesday, February 12th. Zacks Small Cap ...
Arrowhead price target lowered to $38 from $51 at B. Riley
B. Riley lowered the firm’s price target on Arrowhead (ARWR) to $38 from $51 and keeps a Buy rating on the shares following the fiscal Q1 ...
news.stocktradersdaily4h
When (ARWR) Moves Investors should Listen
Check the time stamp on this data. Updated AI-Generated Signals for Arrowhead Pharmaceuticals Inc. (ARWR) available here: ...
Cautious On Arrowhead Pharmaceuticals' FDA NDA Acceptance Due To Valuation Concerns
Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...
Chardan Capital Reiterates “Buy” Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports.
Arrowhead and Sarepta close $500 million licensing deal
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), currently trading at $20.24 and showing an 8% gain ...
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations
First Quarter 2025 Results Key Financial Results Net loss: US$173.1m ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Call Transcript
Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.